| Website | revance.com |
| Category | BioTech |
| Phone | (510) 742-3400 |
| Employees | |
| Description | Dermatology, Aesthetic Medicine |
| TOTAL | $70M |
| VENTURE FUNDING TOTAL | $70M |
| Series D, 1/10 Essex Woodlands Health Ventures Vivo Ventures Technology Venture Partners Shepherd Ventures Pac-Link | $25M |
| Venture Round, 6/11 Essex Woodlands Health Ventures NovaQuest CNF Investments Vivo Ventures Technology Partners Shepherd Ventures Palo Alto Investors | $45M |
Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.
